These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 36254376

  • 1. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
    Liu Y, Qiao Y, Zhou M, Guo J, Lin Y, Li W, An C, Li C.
    Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y, Peng W, Zhang W, Yang Z, Hu Z, Pang Y, Hu D, Chen J, Wang J, Zhou Z, Xu L, Chen M, Zhang Y.
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R, Wang X, Li H, Wang M, Wang J, Wang W, Zhou Q.
    J Hepatocell Carcinoma; 2024 Apr; 11():1727-1740. PubMed ID: 39281003
    [Abstract] [Full Text] [Related]

  • 7. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S, Li D, Lv Y, Wu J.
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y, Zhang H, Xu H, Wang Y, Feng L, Yi F.
    World J Surg Oncol; 2024 May 06; 22(1):122. PubMed ID: 38711095
    [Abstract] [Full Text] [Related]

  • 9. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z, Huang X, Wu Y, Li T, Guo W.
    BMC Cancer; 2021 Oct 19; 21(1):1126. PubMed ID: 34670506
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.
    Long F, Chen S, Li R, Lin Y, Han J, Guo J, Chen Y, Li C, Song P.
    Med Oncol; 2023 Apr 12; 40(5):147. PubMed ID: 37043113
    [Abstract] [Full Text] [Related]

  • 11. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
    Li Y, Liu W, Chen J, Chen Y, Guo J, Pang H, Zhang W, An C, Li C.
    Cancer Med; 2024 Jan 12; 13(1):e6836. PubMed ID: 38196277
    [Abstract] [Full Text] [Related]

  • 12. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study.
    Sun L, Hu Z, Xie W, Yang Z, Zeng H, Zhang Y, Chen M, Hu D, Zhou Z, Pan Y.
    BMC Cancer; 2024 Sep 19; 24(1):1168. PubMed ID: 39300392
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ, Lee HJ, Lee SH.
    Clin Mol Hepatol; 2013 Sep 19; 19(3):288-99. PubMed ID: 24133667
    [Abstract] [Full Text] [Related]

  • 14. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M, Li QJ.
    Technol Cancer Res Treat; 2021 Sep 19; 20():15330338211063848. PubMed ID: 34898313
    [Abstract] [Full Text] [Related]

  • 15. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
    Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, Kim YS, Yim HJ, Um SH, Chung WJ, Hwang JS, Cho SB, Eun JR.
    Cancer Chemother Pharmacol; 2015 Apr 19; 75(4):739-46. PubMed ID: 25663125
    [Abstract] [Full Text] [Related]

  • 16. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
    Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH, Han KH.
    J Cancer Res Clin Oncol; 2011 Apr 19; 137(4):659-67. PubMed ID: 20552225
    [Abstract] [Full Text] [Related]

  • 17. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, Li Q, Xu L, Zhang Y, Wei W, Chen M, Kan A, Shi M.
    Eur J Cancer; 2022 Oct 19; 174():68-77. PubMed ID: 35981413
    [Abstract] [Full Text] [Related]

  • 18. Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma.
    You H, Liu X, Guo J, Lin Y, Zhang Y, Li C.
    Int J Hyperthermia; 2022 Oct 19; 39(1):1097-1105. PubMed ID: 35993224
    [Abstract] [Full Text] [Related]

  • 19. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK.
    J Cancer Res Clin Oncol; 2021 Oct 19; 147(10):3123-3133. PubMed ID: 33893539
    [Abstract] [Full Text] [Related]

  • 20. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X, Li X, Sun P, Li Z, Sun P, Ning S.
    BMC Cancer; 2024 Apr 16; 24(1):480. PubMed ID: 38627684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.